Angelini Acraf
Angelini Industries is a privately held Italian conglomerate operating across pharmaceuticals (Angelini Pharma), consumer goods, and industrial technology, with €1.7 billion in 2025 revenue across 21 countries. The group is expanding internationally via the $4.1 billion Catalyst Pharmaceuticals acquisition.
- Company typePrivate
- Founded2019
- HeadquartersAncona, Italy
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Angelini Acraf does
Angelini Industries (legal entity Angelini Holding S.p.A.) is a privately held Italian conglomerate founded in 1919 and headquartered at Viale Amelia, 70 in Rome. The group operates across three business segments: healthcare/pharmaceuticals (Angelini Pharma), consumer goods (Largo consumo), and industrial technology (Angelini Technologies). Angelini Pharma develops, manufactures, and distributes pharmaceutical products across multiple therapeutic areas, serving healthcare providers (hospitals, pharmacies) and patients globally through a field sales motion and established healthcare distribution networks. The group employs approximately 5,600 people across 21 countries, operates 12 production sites, and generated €1.7 billion in total revenues in FY2025, a 4.6% increase year-over-year, with growth led by the pharmaceutical and industrial technology segments.
Angelini Industries monetizes primarily through pharmaceutical product sales across therapeutic areas, with pricing typically quote-based and subject to market-specific regulatory approval. Distribution is conducted through direct healthcare provider relationships and established institutional channels (hospitals, pharmacies) in the group's 21 operating countries. The consumer goods and industrial technology segments add diversified revenue streams, with the latter encompassing robotics and logistics automation investments.
In July 2026, Angelini Pharma completed its largest-ever transaction — the $4.1 billion (approximately €3.5 billion) acquisition of US-based Catalyst Pharmaceuticals, which specializes in rare disease therapeutics and was delisted from Nasdaq at $31.50 per share (a 21% premium). The acquisition was financed through a €1 billion preferred equity investment from Blackstone, a €1 billion capital increase subscribed by CDP Equity for a 23.5% minority stake, and a syndicated debt package coordinated by BNP Paribas across 14 Italian and international financial institutions. Angelini Technologies complemented this with a May 2026 strategic investment in US-based robotics startup Lab0, Inc. The Angelini family retains majority control of the group.
Angelini Acraf firmographics
Firmographics- Name
- Angelini Acraf
- Legal name
- Angelini Holding S.p.A.
- Website
- https://angelini.it
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Angelini Industries is a privately held Italian conglomerate operating across pharmaceuticals (Angelini Pharma), consumer goods, and industrial technology, with €1.7 billion in 2025 revenue across 21 countries. The group is expanding internationally via the $4.1 billion Catalyst Pharmaceuticals acquisition.
- Ownership category
- akta.pro rank
Where Angelini Acraf is headquartered
LocationHeadquarters
- HQ city
- Ancona
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Angelini Acraf business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical products: Angelini Pharma generates revenue through the development, manufacturing, and sale of pharmaceutical products across multiple therapeutic areas, serving healthcare providers and patients globally.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Angelini Acraf product offering
Product offeringCore offering
Angelini Industries is a diversified Italian conglomerate that produces, markets, and distributes products across three main segments: Health (pharmaceuticals and biopharmaceuticals via Angelini Pharma, including rare disease therapies through acquired Catalyst Pharmaceuticals), Consumer goods (Largo consumo), and Industrial technology (via Angelini Technologies including robotics and logistics automation). The group operates 12 production sites across 21 countries and generated €1.7 billion in total revenues in 2025.
Product overview
Angelini Industries operates as a diversified industrial group with three main business segments: Salute (Health/Pharmaceuticals), Largo consumo (Consumer goods), and Tecnologia industriale (Industrial technology). The pharmaceutical division, led by Angelini Pharma, recently expanded through the acquisition of US-based Catalyst Pharmaceuticals. The company also operates Angelini Academy for corporate training and development. The group generated €1.7 billion in total revenues in 2025 with operations across 21 countries and 12 production sites.
Differentiator
Problem solved
Functional benefit
Products and services
- Angelini Academy Corporate academy providing leadership development, management training, and educational programs for Angelini Industries employees, including an international MBA partnership with IE University of Madrid.
Companies that use Angelini Acraf
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles3 records
Angelini Acraf technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Angelini Acraf partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IE UniversityminorAngelini Academy partnered with IE University of Madrid for an international MBA program, enabling group employees to participate in full-time MBA education as part of the corporate academy's development initiatives.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Angelini Acraf competitors and assessment
Company assessmentBroad incumbents
- Ipsen: Global specialty pharmaceutical company with strong European presence. Comparable as a specialty pharma group operating across multiple therapeutic areas with international commercial infrastructure.
- Henkel: German multinational with consumer goods and adhesive technologies divisions. Comparable as a diversified industrial group balancing consumer-facing businesses with industrial/technology operations.
- 3M Company: Global diversified industrial conglomerate. Comparable as a large diversified industrial group operating across multiple unrelated sectors, providing a benchmark for conglomerate valuation dynamics.
Direct peers
- Recordati: Publicly listed Italian specialty pharmaceutical company. Comparable as an Italian pharma company with established therapeutic area franchises and international commercial reach.
- Bolton Group: Privately held Italian family-owned conglomerate with consumer goods (food, home care) and other industrial operations. Closely comparable as a privately held Italian family-controlled diversified industrial group.
- Zambon: Privately held Italian pharmaceutical company with operations across Europe, the Americas, and Asia. Comparable as a privately held Italian pharma group with established global presence.
- Menarini Group: Privately held Italian pharmaceutical and diagnostics company. Closely comparable as a family-controlled Italian pharma group with both proprietary pharma operations and consumer healthcare/diagnostics exposure.
- Molteni & C. Privately held Italian pharmaceutical company. Comparable as a privately held Italian pharma group with specialty therapeutic focus.
- Chiesi Farmaceutici: Privately held Italian pharmaceutical company with global operations across multiple therapeutic areas. Directly comparable to Angelini Pharma as a privately held Italian pharma group with international expansion ambitions.
- Dompé Farmaceutici: Privately held Italian biopharmaceutical company. Comparable as a privately held Italian pharma with specialty therapeutics focus and growing international footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Angelini Acraf social profiles
Digital presenceAngelini Acraf financial estimates
Financial estimateRevenue estimate
Valuation estimate
Angelini Acraf leadership team
Management profileNumber of profiles
Profiles1 record
Angelini Acraf subsidiaries and ownership
Company hierarchySubsidiaries2 records
Angelini Acraf funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Angelini Acraf M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Angelini Acraf
What does Angelini Acraf do?
Angelini Industries is a diversified Italian conglomerate that produces, markets, and distributes products across three main segments: Health (pharmaceuticals and biopharmaceuticals via Angelini Pharma, including rare disease therapies through acquired Catalyst Pharmaceuticals), Consumer goods (Largo consumo), and Industrial technology (via Angelini Technologies including robotics and logistics automation). The group operates 12 production sites across 21 countries and generated €1.7 billion in total revenues in 2025.
Is Angelini Acraf a public or private company?
Angelini Acraf is a private company. It is classified as family owned and is currently operating.
When was Angelini Acraf founded?
Angelini Acraf was founded in 2019. It employs 5,001 to 10,000 people.
Where is Angelini Acraf based?
Angelini Acraf is headquartered in Ancona, Italy, in the Europe region.
How does Angelini Acraf make money?
One revenue line is on record: pharmaceutical products.
Who are Angelini Acraf's main competitors?
Broad incumbents on record are Ipsen, Henkel and 3M Company. Direct peers are Recordati, Bolton Group, Zambon, Menarini Group, Molteni & C., Chiesi Farmaceutici and Dompé Farmaceutici.
Does Angelini Acraf have an API?
No public API is recorded for Angelini Acraf.